KROS Keros Therapeutics Inc
Price (delayed)
$11.46
Market cap
$464.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5
Enterprise value
-$77.68M
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros
Highlights
KROS's equity has surged by 72% year-on-year and by 7% since the previous quarter
The quick ratio has soared by 51% YoY and by 12% from the previous quarter
The debt has grown by 31% YoY but it has contracted by 2.2% from the previous quarter
The company's net income fell by 22% YoY and by 3.2% QoQ
Key stats
What are the main financial stats of KROS
Market
Valuations
Earnings
Shares outstanding
40.56M
Market cap
$464.84M
Enterprise value
-$77.68M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.81
Price to sales (P/S)
120.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-21.88
Revenue
$3.55M
Gross profit
$3.55M
Operating income
-$210.83M
Net income
-$187.35M
EBIT
-$187.05M
EBITDA
-$184M
Free cash flow
-$162.8M
Per share
Balance sheet
Liquidity
EPS
-$5
EPS diluted
-$5
Free cash flow per share
-$4.35
Book value per share
$14.11
Revenue per share
$0.09
TBVPS
$16.45
Total assets
$615.89M
Total liabilities
$44.33M
Debt
$18.86M
Equity
$571.55M
Working capital
$561.44M
Debt to equity
0.03
Current ratio
21.45
Quick ratio
20.55
Net debt/EBITDA
2.95
Margins
Efficiency
Dividend
EBITDA margin
-5,183.2%
Gross margin
100%
Net margin
-5,277.5%
Operating margin
-5,939%
Return on assets
-35.1%
Return on equity
-37.9%
Return on invested capital
-462.9%
Return on capital employed
-31.8%
Return on sales
-5,269.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KROS stock price
How has the Keros Therapeutics stock price performed over time
Intraday
-2.55%
1 week
-3.94%
1 month
12.91%
1 year
-83.06%
YTD
-27.61%
QTD
-27.61%
Financial performance
How have Keros Therapeutics's revenue and profit performed over time
Revenue
$3.55M
Gross profit
$3.55M
Operating income
-$210.83M
Net income
-$187.35M
Gross margin
100%
Net margin
-5,277.5%
The operating margin has surged by 95% year-on-year and by 81% since the previous quarter
The net margin has soared by 95% YoY and by 81% from the previous quarter
Keros Therapeutics's operating income has decreased by 24% YoY and by 3.3% from the previous quarter
The company's net income fell by 22% YoY and by 3.2% QoQ
Growth
What is Keros Therapeutics's growth rate over time
Valuation
What is Keros Therapeutics stock price valuation
P/E
N/A
P/B
0.81
P/S
120.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-21.88
KROS's EPS is up by 4% since the previous quarter and by 3.8% year-on-year
The price to book (P/B) is 81% lower than the 5-year quarterly average of 4.3 and 77% lower than the last 4 quarters average of 3.6
KROS's equity has surged by 72% year-on-year and by 7% since the previous quarter
KROS's P/S is 97% below its last 4 quarters average of 4926.0
Efficiency
How efficient is Keros Therapeutics business performance
KROS's return on sales has surged by 95% year-on-year and by 81% since the previous quarter
The ROE has grown by 19% YoY and by 9% from the previous quarter
The company's return on assets rose by 18% YoY and by 9% QoQ
The ROIC has grown by 9% from the previous quarter and by 7% YoY
Dividends
What is KROS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KROS.
Financial health
How did Keros Therapeutics financials performed over time
KROS's total assets has soared by 66% YoY and by 6% QoQ
The quick ratio has soared by 51% YoY and by 12% from the previous quarter
The debt is 97% less than the equity
KROS's equity has surged by 72% year-on-year and by 7% since the previous quarter
The debt has grown by 31% YoY but it has contracted by 2.2% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.